Introduction
============

Bone Morphogenetic Protein 13 is a member of the wider Bone Morphogenetic Protein (BMP) family, a group of bio-active growth factors with 20 -- 30% amino acid homology to Transforming Growth Factor β (TGFβ). Initially BMPs were identified as components of de-mineralised bone matrices which stimulate the generation of new bone tissue when implanted ectopically, or at sites of fracture [@B1],[@B2]. BMP13 was identified in cartilaginous tissues, and by virtue of its homology to other members of the BMP family [@B3],[@B4].

More than 30 BMPs have now been identified in a wide range of species. Protein structure and, to a lesser degree amino acid sequences are evolutionarily conserved; and BMPs are present in diverse species such as mammals, fish, amphibians and birds. BMP-like molecular pathways have been identified in invertebrates such as *Drosophila* [@B5]-[@B7] and in the nematode *Caenorhabditis elegans* [@B8],[@B9]. To date BMP13 appears to be vertebrate specific [@B10].

Members of the BMP family have a range of 40-60% amino acid identity but can be divided into subgroups on the basis of structural and amino acid similarities, as listed in Table [1](#T1){ref-type="table"}. BMP13 (GDF6, CDMP2) has a higher degree of homology (80-86% amino acid identity) with other members of the GDF sub family (GDF5/BMP14, GDF7/BMP12) than with the wider BMP group (about 50%) [@B11]-[@B13], indicating the potential for conserved function.

BMPs are considered to be pleiotropic, effecting many different tissues in subtly different ways. They have been identified and characterized through diverse fields of biology such as tissue healing, regeneration and maintenance [@B3],[@B11],[@B12],[@B14]; mouse developmental mutational analysis [@B4],[@B15],[@B16]; Zebrafish and *Xenopus* embryo development [@B17]-[@B19]; and investigations of human developmental anomalies [@B20],[@B21]. BMPs play crucial roles in early embryonic patterning and in skeletal and organ development [@B22]-[@B25].

BMP13 Protein Structure
=======================

The amino acid sequence for BMP13/GDF6 is highly conserved across vertebrates, although to date no invertebrate orthologues have been identified [@B10]. Sequence homology is concentrated in the active C-terminal domain (Figure [1](#F1){ref-type="fig"}) indicating crucial conservation of function. Even the most divergent of BMP13-homologues, Zebrafish *dynamo* and *radar*, display \> 90% homology in this domain. Considerably less sequence similarity is found in the N-terminal pro-domain, although there are conserved regions in higher vertebrates associated with developmental mutations [@B21] (Figure [2](#F2){ref-type="fig"}).

Protein structural information for BMP13 is speculative, relying on the analysis of conserved structural characteristics of members of the BMP family, and based on studies of BMP4 [@B26]-[@B29] and BMP7 [@B30]. The 3-dimensional structure of the BMPs is referred to as a "cysteine knot" [@B31]. Synthesised as large precursor molecules containing a pro-domain and an active domain, BMPs form homodimers in the Endoplasmic Reticulum (ER) and are proteolytically cleaved in the Golgi [@B32] at dibasic consensus RXXR seropeptidase cleavage sites. BMP13 has a consensus sequence for cleavage by a serine pro-protein convertase such as furin [@B33], positioned to release an active C-terminal domain of 121aa (Figure [3](#F3){ref-type="fig"}). Western blotting data under reducing and non-reducing conditions confirms BMP13 exists as a homodimer of approximately 16KDa subunits [@B34]-[@B37], structurally held together by inter- and intra-chain disulphide bonds between 7 conserved cysteine residues (see Figure [3](#F3){ref-type="fig"}). Interestingly the BMP13 amino acid sequence also possesses a second putative dibasic consensus cleavage site upstream in the pro-domain similar to that identified for BMP4 [@B29], indicating that control of the release of active BMP13 may rely on 2 proteolytic cleavage steps within the ER and Golgi (Figure [2](#F2){ref-type="fig"}). An amino acid sequence alignment of this region shows considerable homology across diverse species, and encompasses 2 loci where developmental mutations associated with Klippel-Feil Syndrome have been identified [@B21] (Figure [2](#F2){ref-type="fig"}).

Evidence obtained from purification of bioactive fractions from bone suggest BMPs, in addition to forming homodimers, can form heterodimeric molecules *in vivo* [@B38],[@B39]. *In vitro* studies have implied that BMP2/7 and BMP4/7 heterodimers formed preferentially and had significantly greater activity in osteogenic differentiation assays [@B40],[@B41] and in mesoderm induction in *Xenopus* oocytes [@B42],[@B43] than the two homodimeric molecules combined. BMP13 formed heterodimers with BMP2 when co-expressed in the same cell *in vitro* and may also interact with BMP4 [@B17], however this is yet to be demonstrated *in vivo*. Indeed, any direct evidence of protein processing, structure or physical characteristics specific to BMP13 are as yet unavailable or unpublished.

Receptor Transduced Signalling
==============================

BMP13, like all members of the BMP family, functions via cell signaling through trans-membrane serine-threonine kinase receptor complexes [@B24],[@B44],[@B45] (Table [3](#T3){ref-type="table"}). BMP signal receptor complexes contain both Type I (BMPRIA, BMPRIB, ALK1, ALK2) and Type II (BMPRII, ActRII, ActRIIB) receptor molecules. The homodimeric BMP ligand first binds to a constitutively active type II receptor, which recruits and phosphorylates the type I receptor, conferring ligand binding, kinase domain activation and initiating intracellular signalling cascades [@B24],[@B45],[@B46]. The type I receptor molecules are necessary for the signalling component of the complex [@B47]. BMP receptors are inducible in tissues such as bone, where both BMPRIA/IB increase expression at sites of ossification, and display temporal expression in specific tissues during embryogenesis [@B45].

BMP13 has demonstrated preferential affinity for BMPRIB (Activin receptor-Like Kinase 6 (ALK6)) and BMPRII. In the rat osteoprogenitor cell line ROB-C26 BMP13 formed complexes with BMPRIB and BMPRII which transduced a strong transcription initiation signal, with a weaker signal and barely detectable receptor complex associated with BMPRIA/BMPRII [@B34]. Interestingly, the BMPRIB/BMPRII complex is crucial for chondrogenesis of chick limb mesenchymal cells [@B48], suggesting a role for BMP13 (and closely related GDF family members) in chondrogenic develoment.

The downstream events associated with BMP receptor complex activation involve recruitment and activation of Receptor-associated-Smad signalling molecules (R-Smad), which combine with the common Smad (C-smad), Smad-4, to propagate the BMP receptor signals to the nucleus through their ability to bind to specific DNA sequences and promote gene expression [@B25],[@B49]-[@B52]. BMP13 binding to BMPRIB, BMPRIA and BMPRII results in phosphorylation/activation of Smad 1/5/8, and transcriptional activation via BMP response elements (BRE) *in vitro*[@B53]. Blocking BMP13 (GDF6) signalling *in vivo* results in a reduction in phospho-smad in corresponding regions of the developing embryo [@B19].

BMP13 Expression and Function
=============================

BMP13, was first identified and isolated as a component of bovine cartilage, designated Cartilage Derived Morphogenetic Protein -2 (CDMP2) [@B3], expressed in post natal articular and cricoid cartilage, and to a lesser degree in other tissues such as intestines, skeletal muscle and placenta. Expression has since been detected in a variety of structural tissues and aspects of its function have been emerging. The majority of studies focus on the promotion of connective tissue healing and on comparisons with other BMPs known for their ability to stimulate the growth of bone. However, a body of literature examines BMP13 and its homologues in embryonic development, work that could provide clues to the more specific roles of BMP13 in adult tissues.

BMP13 and Cartilage
-------------------

BMP13 expression has been detected in both foetal and post natal cartilaginous tissues from various species and anatomical sites [@B3],[@B35],[@B36],[@B54],[@B55]. Expression was detected mainly in the upper layers of post natal articular cartilage tissues [@B35] but was uniform in cultured chondrocytes. Examination of human foetal tissues (6 - 10 wks gestation) has localized BMP13 expression to mature and hypertrophic chondrocytes in the periosteal bony collar of developing long bones [@B3].

Chondrocytic cells isolated and cultured *in vitro* respond to recombinant BMP13 stimulation, increasing the biosynthesis of proteoglycan (PG) [@B34]-[@B36],[@B56],[@B57] measured by alcian blue staining, ^35^S-incorporation or as a percentage of tissue wet weight [@B57]. This appears to be, at least in part, due to increased aggrecan mRNA levels [@B36], however more data is required as other study results do not show aggrecan mRNA upregulation [@B35].

BMP13 does not appear to increase chondrocyte or cartilage cell proliferation [@B34],[@B36], although proliferation was reported in a study of mesenchymal progenitor cell differentiation (discussed further below) [@B58]. The location of expression in cartilaginous tissues would suggest a presence in proliferating cells.

Surprisingly, BMP13 stimulation of cartilaginous tissues did not demonstrate increased levels of collagen expression [@B35],[@B36],[@B56], yet collagen II upregulation has been reported in mesenchymal progenitor cells stimulated with BMP13 [@B58],[@B59]. This is perhaps a reflection of the differentiation state of the cells under study, rather than the signals being transduced by the BMP13 ligand.

The measurement of increased catabolic activity in cells stimulated with BMP13, while indicative of activity, was not specific or limited to BMP13 alone. Indeed all CDMPs (BMP13, 12, 14), when compared directly, induced chondrocytic protein synthesis with varying levels of intensity depending on the tissues studied [@B60],[@B61].

BMP13 in Osteogenesis
---------------------

The potential for BMP13 to stimulate osteogenic phenotypes has been examined [@B34],[@B57]-[@B59],[@B62]-[@B64].

Rather than osteogenic differentiation, BMP13 appears to induce marker expression in progenitor cells that are characteristic of chondrocytes, such as proteoglycan [@B34],[@B37],[@B57],[@B58],[@B64] and collagen II [@B58],[@B59]. BMP13 stimulation of a number of different progenitor cell types had no effect on the expression of osteogenic markers osteocalcin [@B57],[@B58],[@B62], myoD [@B63] and calcium mineral accumulation [@B58] that are characteristic of osteogenic differentiation. Further, in a study of human bony outgrowths seen in joint arthritis and known as osteophytes, BMP13 expression was absent from osteoblasts or newly formed osteocytes, rather localized to the proliferating and mature chondrocytes, and to a lesser degree to hypertrophic chondrocytes [@B54].

Some ambiguity exists with respect to BMP13 stimulation of alkaline phosphatase (ALP) activity, which is reportedly increased, albeit to low levels, in mesenchymal progenitor cell lines [@B34],[@B58],[@B59] and BM stromal cells [@B62] in response to recombinant BMP13 stimulation. However other studies in bovine ligament fibroblasts [@B37], periosteum [@B57], and one C2C12 murine progenitor cell line study [@B63] reported no increase in ALP activity. Whilst the ALP studies utilised similar enzyme activity methodology they were done in different cell types, and there was variability in the incubation times (48h to 1-3 weeks), where the longer stimulation times in general resulted in detection of elevated ALP in response to BMP13. It is clear that any enhancement of ALP activity was inferior to that of the more osteogenic BMP7 and BMP2 molecules, and that whilst osteogenesis was not suppressed by BMP13, it was also not significantly enhanced. Interestingly, BMP13 did synergistically enhance the expression of BMP7-induced ALP, myoD and osteocalcin in the C2C12 murine progenitor cell line [@B63], as did all of the CDMPs (BMP13, BMP14 (GDF5) and BMP12 (GDF7)) studied in C2C12 cells- indicating a potential modulator role for BMP13.

These studies also demonstrated that BMP13 showed reciprocal stimulation of mRNA in culture with other BMPs. BMP13 auto-regulated itself and was up-regulated by BMP12 (GDF7, CDMP-3); BMP13 also significantly upregulated the expression of BMP4 mRNA (8-10 fold), and to a lesser degree that of BMP5, GDF8 (myostatin; a negative regulator of skeletal muscle development) and GDF9 (involved in control of ovulation) (2-3 fold), particularly, in the case of GDF8 and 9, following longer incubation periods (6- and 11-fold increases respectively). BMP13 was found to suppress the expression of BMP6 and BMP-8A by 60-70% [@B63]. Taken together, these data point towards a modulator role for BMP13 growth factor signals in the tissue, with an overall enhancement of cartilaginous growth and down regulation of bone-promoting activities.

BMP13 in Tendons & Ligaments
----------------------------

BMP13 expression was detected in human tendon tissues [@B67],[@B68]. Expression was specifically detected at sites of active tissue healing and re-modeling -- particularly in the small, rounded tenoblasts, capable of proliferating and synthesizing tendon extracellular matrix proteins; and in perivascular mesenchymal cells thought to act as stem cells for connective tissue healing [@B68]. *In vitro* BMP13 stimulation induced collagen I expression and, unlike most cellular studies, very low concentrations of recombinant BMP13 (25 -- 50ng/mL) were found to stimulate tenoblast proliferation [@B68]. The active concentration range of BMP13 activity reported in this tendon study has not been duplicated in published studies to date. Whether tenoblasts are particularly responsive to BMP13, or the reagents particularly potent is not known, but clearly the activity was greater than in other published studies which utilise in the vicinity of 200-300ug/mL [@B34]-[@B37],[@B56],[@B59],[@B63],[@B64]. Interestingly it is one of the only studies published where human recombinant proteins were used to stimulate human tissues.

Several studies have reported neo-tendon/ligament formation and the development of highly organized connective tissue rich in collagen I fibres in response to *in vivo* ectopic implantation of BMP13 at sites of tendon wounding in rats [@B61],[@B69],[@B70] and intramuscularly [@B60],[@B71]. Progenitor cell proliferation and differentiation into neo-tendon/neo-ligament was reported within the muscle, the formation of collagenous extracellular matrix, and even development of small bone and cartilage foci within the new tissue [@B71].

Further *in vivo* studies demonstrated that BMP13 has significant ability to accelerate the healing of damaged tendons and ligaments *in vivo*, inducing mechanical strengthening of the tendon fibres which were measurably stronger 8 days following a single injection of recombinant BMP13 [@B61],[@B70]. Intriguingly, researchers found that implantation at physiological sites subject to different mechanical loading stimulated the growth of either bone tissue (unloaded tendons) or cartilaginous tissue (mechanically loaded tendons) [@B69].

It is noteworthy that whilst these tendon tissue studies reported stimulation of collagen I fibre formation, isolated bovine ligament fibroblasts stimulated with BMP13 *in vitro* were induced to express a more chondrogenic phenotype, increasing expression of proteoglycan [@B37]. Taken together with evidence of differential tissue formation in response to mechanical loading, it appears that BMP13 induction of cellular catabolism produces the up-regulation of different sets of genes in different circumstances.

BMP13 in the Intervertebral Disc
--------------------------------

The structure of the intervertebral disc (IVD) is a gelatinous, highly hydrated core - the Nucleus Pulposus (NP), comprised largely of proteoglycan and collagen II, surrounded by a high tensile strength collagen fibre "fence" in the form of the Annulus Fibrosus (AF).

Studies in cells derived from the Nucleus Pulposus (NP) [@B72]-[@B74] and Annulus Fibrosus (AF) [@B73], in comparison to other catabolically active BMPs, have demonstrated that BMP13 induced disc cell catabolic activity. BMP13 stimulated increased production of proteoglycan and total collagen in the absence of increased cell proliferation in IVD monolayer cultures [@B72],[@B73] and in 3D alginate co-culture with transduced chondrocyte monolayers [@B74]. Furthermore the data suggest that AF cell cultures are more responsive to BMP13 than NP cells, producing proportionately more proteoglycan and collagen in relation to controls and in comparison to other BMPs tested [@B73].

In addition, Li et al (2003) have utilized a mouse chondrocytic cell line MC615 to study the potential for BMP13 in combination with BMP2 to stimulate the production of extracellular matrix proteins characteristic of the disc tissue. Whilst this cell line is not derived from the disc it demonstrates similar gene expression. The authors found that both proteins could stimulate the production of proteoglycan, mediated by increased aggrecan mRNA expression, but had little effect on cell proliferation. In this model the stimulatory effect of BMP2 was greater than BMP13, occurred at lower concentrations, and no synergistic activity was detected [@B64].

We have recently obtained early data from a large animal disc degeneration model [@B75] which suggests that BMP13, when injected directly into the disc, can reverse early degenerative changes induced by mechanical injury (Diwan et al 2008, unpublished observations; Approved by the University of Sydney Animal Ethics committee, August 2007). Our study detected a loss of disc integrity using MRI, where an annulus stab injury receiving saline injection was visible as a darker (more degenerated) T2-weighted image compared to those which received BMP13 injection, or uninjured controls (Figure [4](#F4){ref-type="fig"}). Histological analyses revealed an increase in the number of cells discharging into the disc from the discal side of the end plate in BMP13-injected discs, compared to the stab-controls or exposed un-injured controls (Figure [5](#F5){ref-type="fig"}). This was accompanied by evidence of neo-vascularization, a known response to chronic injury and characteristic of this model [@B76], which we observed on the bony side of the end plate region in disc tissues derived from the stab-only controls, yet not in the BMP13-injected disc tissues (Figure [5](#F5){ref-type="fig"}).

Development
===========

Members of the BMP family play crucial roles in developmental processes [@B22],[@B23],[@B65],[@B77]-[@B79] and BMP13 is no exception.

BMP13 was simultaneously cloned by Storm et al (1994) by virtue of its homology to other BMP family members using degenerate PCR primers, delineating a BMP sub-family of "Growth and Differentiation Factors" (GDFs 5, 6, 7), so named due to the mutational effect of GDF5 gene disruption in causing brachypodism in mice [@B4]. BMP13 expression was detected in the developing limb -- restricted to ossifying long bone centres [@B3]. The specific role of BMP13 in developmental processes is not yet clear, although its involvement in human eye development has been reported [@B20]; and homologous genes *radar* [@B18],[@B80] and *dynamo* [@B81] in Zebrafish; and GDF6 homologues in *Xenopus laevis* [@B17] influence early embryonic development.

Embryonic Development
---------------------

BMP signalling pathways have been conserved through evolution from *Drosophila* to mammals, with BMP4 capable of rescuing *Drosophila* decapentaplegic (dpp) mutations [@B82]. Similarly early embryonic development, from fruit fly to mammals, is initiated through positional information provided, at least in part, by BMP morphogens and their antagonists forming activity gradients across the embryo [@B19],[@B51].

Studies of homologous pathways in Zebrafish, *Drosophila* and Frog (*Xenopus laevis*) demonstrate a role for BMP13 in early embryo development. In Zebrafish, a BMP13/GDF6 homolog - *radar*-- influences initial dorso-ventral patterning of the embryo as a maternal RNA transcript [@B18],[@B83]. Over-expression of *radar* in Zebrafish embryos results in a ventralised phenotype with a reduction or absence of dorsal structures [@B83]. Ablution of maternal transcripts results in a dorsalised Zebrafish embryo phenotype [@B80], and also results in perturbed ventro-lateral expression of other BMPs, such as BMP2b and BMP4 [@B80]. A second Zebrafish BMP13/GDF6 homolog, *dynamo*, is not maternally expressed and has more restricted expression, found in posterior ventral neural tissue, eventually becoming restricted to the ventral spinal cord tissues at the end of somatogenesis, suggesting a more specific role in the organization of the developing spinal cord [@B81].

It is not known whether the BMP13/GDF6/*radar* ventralising activity is conserved in other species. Certainly maternal GDF6 (BMP13) RNA transcripts have not been detected in Xenopus embryos [@B17], although protein translated during oogenesis could conceivably be active in the early frog embryo. However injection of wild type BMP13 (GDF6) into early *Xenopus* embryos results in a mild ventralisation phenotype [@B17], similar to that observed in Zebrafish. BMP13/GDF6 induced epidermal genes and inhibited neural markers in *Xenopus* embryos, activities directly modulated by expression of antagonist molecule, *noggin* [@B17].

Eye/retinal development
-----------------------

Studies of human chromosomal abnormalities have recently identified GDF6 (BMP13) within and adjacent to segmental chromosomal deletions in patients with Colobomata [@B20], a complex series of ocular abnormalities that appear to involve many apparently unrelated genes. Ocular development is also perturbed when zygotic expression of Zebrafish GDF6 homologue *radar* is inhibited - morphants exhibit reduced eye, head and dorsal neural tube structures [@B80].

Similarly, BMP13 was also identified as an early regulator of retinal development in a *Xenopus* model [@B19]. Phenotypically, depletion of GDF6 resulted in a reduction in eye size, evidence of increased programmed cell death, more disorganized retinal tissue development, and the presence of neural defects in the eye and neural tube [@B19],[@B21]. The influence of BMP13 depletion also extended to wider influences on developing neural tissue and the effects correlated with a decrease in phosphorylated smad 1/5/8 signalling molecules, indicative of decreased signalling.

Thus the importance of BMP13/GDF6 and its homologues in embryonic ocular tissue development appears to be conserved across widely variant vertebrate species.

Skeletal development
--------------------

As shown in Figure [1](#F1){ref-type="fig"} & [2](#F2){ref-type="fig"}, BMP13, like all members of the GDF sub-family of BMPs, is highly conserved in vertebrates [@B10]. All GDF genes are expressed in a stripe pattern in developing joint regions where skeletal segmentation events occur [@B16],[@B84], with GDF6/7 expression more restricted than GDF5.

GDF6/BMP13 knockout mice are viable and survive to adulthood, however they have abnormal skull joint development and bone fusions at wrist and ankle -- sites of major BMP13 developmental expression [@B84]. Evidence from studying these mice suggested that development of these joints was initiated normally but could not proceed, suggesting a role for BMP13 in the maintenance of developmental processes.

Naturally occurring null mutations in GDF5 cause brachypodism - shortening of long bones, alterations to joint bone formation in wrists, ankles and digits - and are characterized by abnormal cartilage and some bone fusions [@B16],[@B85]. The combination GDF5/6 knockout mouse is far less viable and has additional striking skeletal defects: many limb bones and joints are severely reduced or absent. In addition the vertebral column appears prone to curvature (scoliosis) in many double mutants, with lower thoracic/lumbar vertebrae displaying altered extracellular matrix (proteoglycan) deposition in inter-vertebral chondrocyte-like cells [@B84]. The authors suggest the GDF knockout mutations exposed a role in joint maintenance and the double knockout may suggest that, rather than representing redundancy of function, members of the GDF family co-operate or rely on each other during skeletal development - and potentially in tissue maintenance.

Recently GDF6 was identified as a candidate gene defect present in several familial and sporadic cases of Klippel Feil Syndrome (KFS) [@B21]. KFS is characterized by heterogeneous congenital defects of the spine, limbs and organ functions [@B86],[@B87]. Breakpoint analysis indicated the involvement of a long range BMP13 regulatory locus in the manifestation of KFS, but also identified two point mutations associated with a familial inherited abnormality (A249E), and two sporadic mutations causing the same syndrome (L289P) (Figure [3](#F3){ref-type="fig"}) [@B21]. Both missense mutation sites are located in the pro-domain in the evolutionarily conserved region near the second putative protease cleavage site, further strengthening the possibility that this site is important for the control of BMP13 tissue expression.

BMP13 Antagonists
=================

BMP antagonists form a protein family that display amino acid homology and evolutionary conservation, possessing a similar "cysteine knot" structure, they are part of the wider TGF-β superfamily [@B15]. In terms of embryo development, early studies with *Xenopus* and *Drosophila* found that morphogenic gradients of opposing antagonistic proteins controlled spatial organization in the embryo and led to the establishment of a dorso-ventral axis [@B88]. BMP antagonists control all aspects of BMP function including effects on tissue re-modelling. They bind to the BMP ligands and prevent interaction with cell surface receptors, thereby blocking intracellular signalling. [@B25].

The GDF6 homolog in *Xenopus* was cloned through a gene screen specific for molecules down-regulated by BMP antagonist Noggin, and direct binding of noggin to GDF6 (BMP13) has been demonstrated [@B17]. Whilst GDF6 was responsible for promoting epidermal tissue modulation, noggin activity induced neural tissues, with normal development the result of a delicate balance between opposing morphogen expression.

Interestingly null noggin mutations have excess cartilage and bone [@B24]. Excess BMP activity as a result of noggin reduction or antagonism may enhance recruitment of cells to cartilage, resulting in oversized growth plates.

Summary and Future directions
=============================

The highly conserved amino acid sequence of the BMP13 active domain -- both within its GDF-subfamily and, quite strikingly, across diverse vertebrate species -- suggests a crucial biological function. The literature to date, whilst providing important insights, appears to imply BMP13/GDF6 functions co-operatively and is somewhat redundant, even playing a modulatory role affecting the functions of other BMPs both in development and in adult tissues.

Reports have emerged showing the genetic impact of BMP13 (GDF6) gene disruption in Zebrafish, *Xenopus*, and in Human individuals; with diverse effects on embryonic ocular and neural tissues, and on the development of skeletal structures such as the skull, limb joints, the developing spinal column and intervertebral discs. Developmental models indicate a very early dorso-ventral patterning function for BMP13/GDF6, which appears to be conserved -- at least in fish and amphibians -- establishing the early dorso-ventral axis and promoting ventral tissues of the eye, head and neural tube. A conserved role is also apparent in the development of ocular structures. The effect of BMP13 in development seems to lie in its influence upon other members of the BMP family and their antagonists, creating downstream patterns of expression of genes which have documented roles in development of the embryo.

In adult tissues, many studies have shown the stimulatory effects of BMP13 on connective tissue marker gene expression, but BMP13 appears, in most cases, to be no more effective than other GDF\'s or BMPs, often showing a lesser catabolic effect, at least *in vitro*. Future studies targeted at understanding the BMP13 signalling pathway would be of interest, particularly using a human protein / tissue combination, to determine specific markers of BMP13 activity aside from other, more extensively characterized BMPs. It would also be of interest to determine the contribution of the second putative protease cleavage site in the BMP13 pro-domain to controlling BMP13 expression and activity -- particularly in view of the point mutations that have been identified in this region in conjunction with the manifestation of Klippel-Feil Syndrome and mal-developed intervertebral discs.

There appears to be redundancy in the functions of various GDF and BMP family members such that more than one protein has an effect on a particular tissue. However perhaps these proteins have such precise functions, are expressed in highly specific tissue regions with exact precision, such that what appears to be redundancy is in fact a carefully orchestrated co-operative interplay across the tissue landscape. Morphogenetic gradients created by increasing and decreasing concentrations of morphogens and antagonists that continue to operate in complex tissues, giving them their characteristics and functional delineations.

Clearly BMP13 function remains an unveiling story, a multi-faceted, pleiotropic morphogen some parts of the vertebrate body just can\'t do without.

![**Alignment of the BMP13 C-terminal active domain amino acid sequence from various vertebrate species**. Shaded areas represent amino acid differences compared to the human sequence. Consensus protease cleavage site (boxed). Accession numbers for sequences: Human-NM_001001557; Rhesus Macaque -- XM_001090825; Mouse-MGI95689; Rat-NM_001013038; Bovine-U13661; Xenopus-AAD38402; Radar (Zebrafish)-AAB34226; Dynamo (Zebrafish)-X99769.](ijbsv04p0318g01){#F1}

![**Alignment of amino acid sequences surrounding the putative BMP13 second cleavage site.**Amino acid sequences alignment demonstrates homology upstream and downstream of a second consensus protease cleavage site (boxed). Residues highlighted in Red are particularly conserved.](ijbsv04p0318g02){#F2}

![**BMP13 Protein Sequence.**Amino acid sequence of human BMP13 showing signal peptide, disulphide-bonded cysteine pairs, consensus protease. Cleavage sites and point mutations identified in degenerative conditions.](ijbsv04p0318g03){#F3}

![**Retention of disc integrity in the presence of BMP13 following annular injury.** Magnetic Resonance Image (MRI) scan of sheep spine at 4 months post surgery. Three disc levels are shown: stab control (annular stab with a No. 9 blade followed by injection of 70uL saline solution), Un-injured control (no injury), BMP13 (annular stab with a No. 9 blade followed by injection of 70uL BMP13 solution).](ijbsv04p0318g04){#F4}

![**Increased cellularity of end plate in the presence of BMP13 following annular stab injury.**Histological analysis of sheep disc tissues 4 months post surgical injury.](ijbsv04p0318g05){#F5}

###### 

BMP protein family sub-grouping by amino acid homology (\*Homology in C-terminal active domain).

  BMP sub-group   Amino acid homology to BMP13 sub-group\*   Alternative Name
  --------------- ------------------------------------------ ------------------
  BMP-2           56-57%                                     BMP2A
  BMP-4           BMP2B                                      
  BMP-6           50-54%                                     Vgr-1
  BMP-7           OP-1                                       
  BMP-5                                                      
  BMP-8           OP-2                                       
  BMP-3           46-47%                                     Osteogenin
  BMP-12          82%                                        GDF-7 / CDMP-3
  BMP-13          100%                                       GDF-6 / CDMP-2
  BMP-14          82%                                        GDF-5 / CDMP-1

###### 

BMP13/GDF6/CDMP2 sequence identification.

  Species          Name       Reference                                         Tissue                                   Accession No.
  ---------------- ---------- ------------------------------------------------- ---------------------------------------- ----------------------
  Bovine           CDMP-2     Chang et al 1994                                  Articular cartilage                      U13661
  Human            BMP13      Strausberg et al 2002, Asai-Coakwell et al 2007   -mixed -genomic DNA sequencing project   AAH4322 NM_001001557
  Rhesus Macaque   Gdf6       Lowe & Eddy 1997                                  Genomic DNA sequencing project           XM_001090825
  Mouse            GDF6       Storm et al 1994                                  12.5d embryo                             MGI 95689
  Rat              GDF6       Sena et al 2003                                   Mandibular molar                         RGD: 620104
  Zebra fish       *radar*    Rissi et al 1995                                  Early embryo                             AAB34226
  Zebra fish       *dynamo*   Bruneau & Rosa 1997                               Early Embryo                             X99769
  Xenopus          GDF6       Chang & Hemmati-Brivanlou 1999                    Mid-gastrula embryo                      AAD38402

###### 

BMP Receptor groupings and nomenclature.

  Receptor   Alternative Name   Type   BMPs Bound
  ---------- ------------------ ------ ------------------------
  ALK3       BMP-RIA            I      2, 4, 7, 13, 14
  ALK6       BMP-RIB            I      2, 4, 7, 13, 14
  ALK1                          I      
  ALK2       Activin RI         I      2, 7, 14, activin
                                       
  BMP-RII                       II     2, 4, 7, 13, 14
  Act-RIIA                      II     7, 2, 13, 14, activins
  Act-RIIB                      II     2, 7, 14, activins

###### 

BMP family members and major functional activities. References: [@B65],[@B66]

  BMP           Other names   Known Activity
  ------------- ------------- -----------------------------------------------------------------------------------------------
  BMP2          BMP2A         Cartilage/bone morphogenesis; osteoblasts differentiation; retinoid mediator
  BMP3          \-            Osteogenesis, bone formation; brain
  BMP4          BMP2B         Cartilage/bone morphogenesis; formation teeth, limbs, & bones from mesoderm; fracture repair
  BMP5          \-            Bone morphogenesis; cartilage development
  BMP6          \-            Hypertrophy-cartilage/skin; adult joint integrity
  BMP7          OP-1          Bone morphogenesis, differentiation; eye and kidney development; osteoblasts differentiation;
  BMP8          OP-2          Bone formation; cartilage development
  BMP8A BMP8B                 Germ cells of testis - spermatogenesis
  BMP9          \-            Chondrogenic differentiation from mesenchymal progenitors
  BMP12         GDF7          Ligament & tendon development
  BMP13         GDF6          Cartilage development, hypertrophy; embryonic patterning; eye development; limb morphogenesis
  BMP14         GDF5          Limb morphogenesis; chondrogenesis; mesenchymal condensation
                GDF8          Negative regulation of skeletal muscle growth
                GDF9          Control of ovulation; expressed in oocytes, ovary
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